Spyre Therapeutics
SYRE
31 hedge funds and large institutions have $42.9M invested in Spyre Therapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 5 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
12% more capital invested
Capital invested by funds: $38.1M → $42.9M (+$4.74M)
0.19% more ownership
Funds ownership: 47.43% → 47.63% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 32 → 31 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.18M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$543K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$111K |
| 4 |
Renaissance Technologies
New York
|
+$94.4K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$76.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$639K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$576K |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$190K |
| 4 |
SIM
Spark Investment Management
New York
|
-$151K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$86K |
SYRE Hedge Fund Activity: Q4 2017 in Review
31 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2017, worth a combined $42.9M — up 12% from $38.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SYRE and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 11 added.
The largest buyer was Nantahala Capital Management, adding an estimated $1.18M. The largest seller was Sio Capital Management, exiting entirely with an estimated $639K sold.
- 31 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2017, down from 32 in Q3 2017.
- Funds reported $42.9M of Spyre Therapeutics stock for Q4 2017, up 12% quarter-over-quarter.
- 4 funds opened new Spyre Therapeutics positions in Q4 2017 and 5 closed out, a net change of -1 holder.
- The largest Spyre Therapeutics buyer in Q4 2017 was Nantahala Capital Management, an estimated $1.18M added.
- The largest Spyre Therapeutics seller in Q4 2017 was Sio Capital Management, an estimated $639K sold.
Based on aggregated 13F filings for Q4 2017.